Mark A. Kay serves as Executive at LogicBio Therapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Mark A. Kay has executed 2 insider transactions totaling $0, demonstrating a balanced approach to their equity position. Their most recent transaction on Nov 16, 2022 involved selling 784,557 shares valued at $0.
Mark A. Kay currently holds 2,199 shares of LogicBio Therapeutics, Inc. (LOGC), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Mark A. Kay has been a net neutral trader of LOGC stock. They have purchased $0 and sold $0 worth of shares.
Mark A. Kay's most recent insider trade was on Nov 16, 2022, when they sold 784,557 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted
| 2,199 |
| $N/A |
| Discretionary |